Physician profile
Swati S Kumar
NPI 1548464118
$10,665.17
in general payments reported to CMS, 2019-2025
38 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $1,287 · 2021: $791 · 2022: $1,287 · 2023: $3,316 · 2024: $1,147 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,579 · Consulting Fee: $2,000 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,578.86 |
| Consulting Fee | $2,000.00 |
| Education | $169.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,317.58 | 2019-2025 | Evenity, Enbrel, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,281.70 | 2020-2025 | Ofev, Jardiance |
| Horizon Therapeutics Plc | $1,276.13 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $558.94 | 2019-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $548.31 | 2022-2025 | Saphnelo |
| Abbvie INC. | $465.53 | 2019-2025 | |
| Ucb, INC. | $393.65 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $239.61 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $220.85 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $213.00 | 2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $206.80 | 2021-2023 | Lupkynis |
| Radius Health, INC. | $186.23 | 2019-2024 | Tymlos |
| Mallinckrodt Enterprises LLC | $173.78 | 2019 | |
| Mallinckrodt Hospital Products INC. | $172.16 | 2020-2025 | Acthar |
| Genzyme Corporation | $162.66 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $140.46 | 2019-2025 | Jesduvroq, Shingrix, Arexvy |
| Vifor Pharma, INC. | $105.31 | 2019-2023 | Veltassa |
| Janssen Scientific Affairs, LLC | $101.39 | 2019 | |
| Calliditas Therapeutics US INC. | $98.27 | 2022-2024 | Tarpeyo |
| Pacira Therapeutics, INC. | $93.36 | 2019-2021 | |
| Ardelyx, INC. | $82.28 | 2024-2025 | Ibsrela |
| Abbott Laboratories | $79.32 | 2024-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $64.54 | 2022-2025 | |
| Shield Therapeutics INC | $64.34 | 2024 | |
| Octapharma USA, INC. | $63.46 | 2021 | |
| Pfizer INC. | $55.18 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.27 | 2021-2023 | Orencia |
| Otsuka America Pharmaceutical, INC. | $45.02 | 2019 | |
| Genentech USA, INC. | $39.71 | 2022 | |
| Medtronic, INC. | $36.78 | 2022-2023 | Minimed 770g |
| Janssen Pharmaceuticals, INC | $30.91 | 2022 | |
| Celgene Corporation | $23.58 | 2019 | |
| Depuy Synthes Sales INC. | $23.10 | 2019 | |
| Cormedix INC. | $22.41 | 2024 | Defencath |
| Sandoz INC. | $20.76 | 2023 | Hyrimoz |
| Cumberland Pharmaceuticals, INC. | $12.79 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.